CN116919879A - Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof - Google Patents
Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof Download PDFInfo
- Publication number
- CN116919879A CN116919879A CN202310892869.0A CN202310892869A CN116919879A CN 116919879 A CN116919879 A CN 116919879A CN 202310892869 A CN202310892869 A CN 202310892869A CN 116919879 A CN116919879 A CN 116919879A
- Authority
- CN
- China
- Prior art keywords
- skin
- probiotics
- composition
- biological
- care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 96
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 40
- 238000000855 fermentation Methods 0.000 claims abstract description 39
- 230000004151 fermentation Effects 0.000 claims abstract description 37
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 34
- 244000068988 Glycine max Species 0.000 claims abstract description 31
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 30
- 230000000529 probiotic effect Effects 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 206010002198 Anaphylactic reaction Diseases 0.000 claims abstract description 12
- 208000003455 anaphylaxis Diseases 0.000 claims abstract description 12
- 230000036783 anaphylactic response Effects 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 238000005516 engineering process Methods 0.000 claims abstract description 7
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 7
- 230000008439 repair process Effects 0.000 claims abstract description 6
- 206010000496 acne Diseases 0.000 claims abstract description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 3
- 239000002781 deodorant agent Substances 0.000 claims abstract description 3
- 239000006166 lysate Substances 0.000 claims abstract description 3
- 229940093882 musclecare Drugs 0.000 claims abstract description 3
- 210000004761 scalp Anatomy 0.000 claims abstract description 3
- 235000003687 soy isoflavones Nutrition 0.000 claims abstract description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 28
- 241001608472 Bifidobacterium longum Species 0.000 claims description 28
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 27
- 244000199866 Lactobacillus casei Species 0.000 claims description 25
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 25
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 25
- 229940017800 lactobacillus casei Drugs 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 22
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 21
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 21
- 239000004365 Protease Substances 0.000 claims description 16
- 150000002333 glycines Chemical class 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 11
- 102000004317 Lyases Human genes 0.000 claims description 8
- 108090000856 Lyases Proteins 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 230000009089 cytolysis Effects 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000004382 Amylase Substances 0.000 claims description 4
- 102000013142 Amylases Human genes 0.000 claims description 4
- 108010065511 Amylases Proteins 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 235000019418 amylase Nutrition 0.000 claims description 4
- 235000020712 soy bean extract Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 description 44
- 239000000243 solution Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 238000004321 preservation Methods 0.000 description 16
- 238000012258 culturing Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 241000191963 Staphylococcus epidermidis Species 0.000 description 13
- 108010003272 Hyaluronate lyase Proteins 0.000 description 12
- 102000001974 Hyaluronidases Human genes 0.000 description 12
- 108090000526 Papain Proteins 0.000 description 12
- 229960002773 hyaluronidase Drugs 0.000 description 12
- 229940055729 papain Drugs 0.000 description 12
- 235000019834 papain Nutrition 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 241000736262 Microbiota Species 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 6
- 229940107187 fructooligosaccharide Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000009629 microbiological culture Methods 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 238000009631 Broth culture Methods 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 102000004139 alpha-Amylases Human genes 0.000 description 5
- 108090000637 alpha-Amylases Proteins 0.000 description 5
- 229940024171 alpha-amylase Drugs 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940068140 lactobacillus bifidus Drugs 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
The invention belongs to the technical field of cosmetics, and particularly relates to a biological probiotics composition with a skin microecology regulating effect, and a preparation method and application thereof. The bioprotein composition comprises soy isoflavones, soy amino acids, probiotic lysates, and probiotic fermentation products. The biological probiotics composition is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics. The invention also relates to the use of a bio-prebiotic composition for the preparation of a cosmetic for regulating the microecological balance of the skin. The cosmetic has effects of regulating skin microecology, maintaining weak acidic function of skin, relieving skin anaphylaxis, inhibiting inflammatory factor in anaphylaxis, and promoting skin repair, and can be used for daily skin care, sensitive muscle care, acne skin care, deodorant care, infant skin care or scalp care.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a biological probiotics composition with a skin microecology regulating effect, and a preparation method and application thereof.
Background
Skin is the largest organ of the human body and is colonized by billions of microorganisms (bacteria, yeasts, fungi, viruses, etc.), collectively referred to as "skin microbiota". Among these microbial flora, the ones classified into resident flora and transient flora. The resident flora consists of symbiotic bacteria, i.e. survive the host without causing any damage. Transient flora consists mainly of harmless fungi, viruses and bacteria, called saprophytes. The flora is not permanent and depends on the activity performed and the change in surrounding conditions and the exposure of the individual to these conditions. These microorganisms are vital. Normally, i.e. when the hygiene is good and when the resident flora, immune response and barrier function of the skin are intact, resident and transient microorganisms do not cause diseases or dysfunctions. The skin microbiota is thus able to act as a barrier and protect its host. When the skin microbiota is unbalanced, the barrier function of the muscle bottom can be destroyed and lost, and harmful bacteria grow, so that the skin is easy to generate diseases such as oil, acne, comedo and the like.
However, the use of currently popular skin care products and cosmetics can disrupt the balance of the skin microbiota. Applications such as foundations can interfere with the balance of the skin microbiota, particularly by interfering with bacterial diversity. Invisible cosmetic films of skin care products on the skin can temporarily change the water-fat balance of the skin and produce desquamation, which can destroy the balance of skin microbiota.
In 2001, consultants of the united nations grain and farming organization (FAO) and the World Health Organization (WHO) define probiotics as "live microorganisms" based on their health and nutritional characteristics in food, and taking appropriate amounts would bring benefits to the health of the host. Probiotic formulations are common treatments for infectious enteritis, or for external bacterial invasion leading to an imbalance in intestinal flora. Research according to Transparency Market Research shows that the U.S. probiotic, prebiotic and other digestive acid product market reaches $68.8billion, even $83.5billion in 2022. In addition, the concept of applying probiotic formulations directly to the skin to improve the skin microbiota has been proposed for a long time, but related products that have been successfully marketed and are very effective are less common.
The present inventors have long focused on the study of skin external products containing probiotics. Heretofore, a ternary probiotic factor composition for regulating skin microecological balance was successfully developed by taking a plurality of probiotics screened by the county of Bama Yao nationality of Country and Chinese people Ruishen of the world as a basis, integrating a modern biological fermentation technology and taking the prebiotics as nutrition sources of the probiotics (see CN 202310172438.7).
In the invention, the inventor discovers that the combined action of the specific types and proportions of the compound probiotics, the prebiotics and the compound enzyme can decompose and recombine macromolecular organic matters in the soybean raw material for the first time, and meanwhile, the biological prebiotic composition with stronger efficacy for regulating the microecological balance of skin can be formed through complex biochemical action.
Disclosure of Invention
The invention overcomes the defects of the prior art and provides a biological probiotics composition with the effect of regulating skin microecology and a preparation method and application thereof. The biological probiotics composition has multiple effects of regulating skin microecology, maintaining weak acidic functions of skin, relieving skin anaphylaxis, inhibiting inflammatory factors in anaphylaxis and promoting skin repair.
Specifically, the invention is realized through the following technical schemes:
in a first aspect, the present invention provides a bio-prebiotic composition comprising soy isoflavones, soy amino acids, probiotic lysate and probiotic fermentation product, having the effect of modulating skin micro-ecology.
Alternatively, in the above-mentioned bio-prebiotic composition, the bio-prebiotic composition is prepared by a bio-fermentation technique from the following raw materials: soybean, probiotics and prebiotics.
Alternatively, in the above-described bio-prebiotic composition, the probiotic is selected from one or more of the following: lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei or bifidobacterium lactis; the prebiotic is selected from one or more of the following: lactose, sucrose, fructo-oligosaccharides, galacto-oligosaccharides or malto-oligosaccharides.
Alternatively, in the above-described bio-prebiotic composition, lactobacillus rhamnosus, bifidobacterium longum and bifidobacterium adolescentis are isolated from the intestinal tract of healthy adult humans in the Guangxi Bama longevity village; streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis are isolated from self-made fermented yoghurt by herdsmen in Yili, xinjiang.
Alternatively, in the above-described bio-prebiotic composition, the probiotic is lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis; the prebiotics are fructo-oligosaccharides and galacto-oligosaccharides.
Preferably, the weight ratio of lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis is 1:1:1:1:1.
Preferably, the weight ratio of fructo-oligosaccharide to galacto-oligosaccharide is 1:1.
Alternatively, in the above-described bio-prebiotic composition, the probiotic Lactobacillus rhamnosus, lactobacillus casei, lactobacillus bifidus, bifidobacterium longum, streptococcus thermophilus are available from Jia Yi bioengineering Co., ltd.
The lactobacillus rhamnosus (Lactobacillus rhamnosus) has a strain preservation number of CGMCC NO.16103 and a preservation date: and on the 7 th and 12 th days of 2018, the strain is preserved in China general microbiological culture Collection center (China Committee) with the address of a preservation unit being China academy of sciences of China, including national institute of sciences of China, no. 3, including the Korean area of Beijing, as seen in CN109055278A.
The lactobacillus casei (Lactobacillus casei) has a strain preservation number of CGMCC NO.21373 and a preservation date: the microorganism strain is preserved in China general microbiological culture Collection center (China Committee for culture Collection) at the address of China center for 14 days in 12 months in 2020, and the China center for microbiological study, including North West Lu No.1, 3, which is the Korean area of Beijing, is referred to as CN112625983A.
The bifidobacterium lactis (Bifidobacterium lactis) strain has a preservation number of CGMCCNO.18093 and a preservation date: the 2019, 07 and 08 are preserved in China general microbiological culture Collection center (China Committee for culture Collection), and the address of a preservation unit is China national academy of sciences of China, including national institute of sciences of China, no. 3, north Chen West Lu 1, korea, beijing, city, and the like, and the preservation unit is CN112625983A.
The bifidobacterium longum (Bifidobacterium longum) has a strain preservation number of CGMCC NO.18094 and a preservation date of: the 2019, 07 and 08 are preserved in China general microbiological culture Collection center (China Committee for culture Collection), and the address of a preservation unit is China national academy of sciences of China, including national institute of sciences of China, no. 3, north Chen West Lu 1, korea, beijing, city, and the like, and the preservation unit is CN112625983A.
The streptococcus thermophilus (Streptococcus thermophilus) has a bacterial preservation number of CGMCC NO.18045 and a preservation date: and on 27 months in 2019, the strain is preserved in China general microbiological culture Collection center (China Committee for culture Collection), and the address of a preservation unit is China academy of sciences of China, including national institute of microbiology, no.1, no. 3, of the North Chen West Lu, korea, beijing, city.
Alternatively, in the above-mentioned bio-prebiotic composition, the probiotic bifidobacterium adolescentis is bifidobacterium adolescentis (Bifidobacterium adolescentis) purchased from the China industry microbiological culture Collection center, and the culture collection number is: CICC 6175.
Alternatively, in the above biological probiotic composition, the probiotics are lactobacillus rhamnosus CGMCC No.16103, bifidobacterium longum CGMCC No.18094, bifidobacterium adolescentis CICC 6175, streptococcus thermophilus CGMCC No.18045, lactobacillus casei CGMCC No.21373 and bifidobacterium lactis CGMCC No.18093.
In a second aspect, the present invention provides a method of preparing a bio-prebiotic composition as described in the first aspect above, comprising the steps of:
(1) Pulverizing semen glycines, extracting with hot water, adding complex enzyme into the extractive solution, centrifuging, collecting semen glycines extractive solution, sterilizing at high temperature, and cooling to 37deg.C;
(2) Adding probiotics and prebiotics into the soybean extract prepared in the step (1), and fermenting at low temperature for 24 hours;
(3) After fermentation, adding lyase to perform lysis on the probiotics, dissolving out intracellular active substances, and filtering by a microporous filter membrane to remove insoluble substances to obtain the biological probiotics composition.
Alternatively, in the above preparation method, in step (1), the complex enzyme is selected from one or more of the following: amylase, saccharifying enzyme or protease, and the enzymolysis temperature is 55 ℃.
Preferably, the complex enzyme is selected from the group consisting of amylase, saccharifying enzyme and protease.
More preferably, the weight ratio of amylase, saccharifying enzyme, protease is 1:1:1.
Further preferably, the protein content of the soybean extract is 0.5% by weight.
Preferably, the temperature of the hot water extraction is 90 ℃ and the extraction time is 3 hours.
Further preferably, the high temperature sterilization temperature is 90 ℃, and the conditions of the post-sterilization centrifugation treatment are 8000rpm for 10min.
Alternatively, in the above preparation method, in the step (2), the content of the probiotics is 0.1% by weight.
Preferably, the probiotics are complex probiotics, which are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis.
More preferably, the weight ratio of lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis is 1:1:1:1:1.
It is also preferred that the prebiotic content is 2% by weight.
Still more preferably, the prebiotic is fructo-oligosaccharide and galacto-oligosaccharide in a weight ratio of 1:1.
Further preferably, the low temperature is 30 ℃.
Alternatively, in the above preparation method, in step (3), the lyase is lysozyme or papain.
Preferably, the lysozyme is added in an amount of 1% by weight and the papain is added in an amount of 0.1% by weight.
Further preferably, the pore size of the microporous filter membrane is 0.45 μm.
In a third aspect, the present invention provides the use of a bio-prebiotic composition as described in the first aspect above or a bio-prebiotic composition prepared by a method of preparation as described in the second aspect above in the manufacture of a cosmetic for regulating the microecological balance of skin.
Alternatively, in the above-mentioned uses, the cosmetic has the effects of regulating skin micro-ecology, maintaining weak acid function of skin, relieving skin allergy, inhibiting inflammatory factors in allergy, and promoting skin repair.
Alternatively, in the above-mentioned use, the cosmetic is used for daily skin care, sensitive muscle care, acne skin care, deodorant care, infant skin care or scalp care.
Alternatively, in the above-mentioned use, the cosmetic is a toner, an emulsion, an essence, a cream or a mask.
Alternatively, in the above use, the amount of the bio-prebiotic composition in the cosmetic is 1% to 10% by weight.
Preferably, the amount of the bio-prebiotic composition in the cosmetic is 1% -5% by weight.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. Is limited to a space and will not be described in detail herein.
Compared with the prior art, the invention has the following beneficial effects:
(1) The invention discovers that the comprehensive actions of the specific types and proportions of the compound probiotics, the prebiotics and the compound enzyme can decompose and recombine macromolecular organic matters in the soybean raw material for the first time, and meanwhile, the biological prebiotic composition with stronger efficacy for regulating the microecological balance of skin can be formed through complex biochemical actions.
(2) The biological probiotics composition has the composite effects of regulating skin microecology, maintaining weak acidic functions of skin, relieving skin anaphylaxis, inhibiting inflammatory factors in anaphylaxis and promoting skin repair.
(3) The biological probiotics composition provided by the invention can not generate drug resistance after long-term use, has no side effect, and is very safe and reliable.
Drawings
Fig. 1: schematic flow chart of the experiment of the proliferation of staphylococcus epidermidis.
Fig. 2: the biological probiotics composition has the function of maintaining the weak acidity of the skin.
Fig. 3: effect example 4 experimental area after histamine sensitization test results.
Fig. 4: effect example 4 Tivi index comparison of experimental area test results after histamine sensitization.
Detailed Description
The invention will be further illustrated with reference to specific examples. It should be understood that the detailed description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
Preparation examples:
example 1:
a biological probiotics composition with skin microecology regulating effect, which is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics, the preparation method of the biological prebiotic composition comprises the following steps:
(1) Pulverizing semen glycines to 80 mesh, extracting with 90 deg.C hot water for 3 hr, cooling the extractive solution to 55deg.C, adding complex enzyme (0.1% alpha-amylase, 0.1% saccharifying enzyme, 0.1% papain) in weight percentage, performing enzymolysis for 2 hr, centrifuging at 8000rpm for 10min, collecting semen glycines extractive solution (protein content of 0.5% in weight percentage), sterilizing at 90deg.C, and cooling to 37deg.C;
(2) Preparing a bottom sugar solution: 1% of galacto-oligosaccharide and 1% of fructo-oligosaccharide are dissolved by purified water according to the weight percentage of the soybean fermentation liquid, and after sterilization at a high temperature of 90 ℃, the mixture is fed into the soybean extraction liquid prepared in the step (1) for one time before fermentation to obtain the soybean fermentation culture liquid;
(3) Preparing seed liquid: preparing seed liquid broth culture solution (1% of casein enzyme digest by weight percent)Sterilizing beef extract powder 1%, yeast extract powder 1%, and glucose 2%, cooling to 37deg.C, inoculating strain tube containing Lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and Bifidobacterium lactis, culturing in anaerobic shake flask at 37deg.C for 8 hr, and culturing to obtain bacterial liquid OD 600 About 1, wherein the probiotics are lactobacillus rhamnosus CGMCC NO.16103, bifidobacterium longum CGMCC NO.18094, bifidobacterium adolescentis CICC 6175, streptococcus thermophilus CGMCC NO.18045, lactobacillus casei CGMCC NO.21373 and lactobacillus bifidus CGMCC NO.18093, and the probiotics are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis in a weight ratio of 1:1:1:1:1:1:1;
(4) Inoculating the probiotic bacteria seed liquid prepared in the step (3) according to the proportion of 0.1% in the soybean fermentation culture liquid treated in the step (2) under the protection of flame, and fermenting for 24 hours at the low-temperature anaerobic temperature of 30 ℃;
(5) After fermentation, inactivating the bacterial activity at 75 ℃, cooling to 55 ℃, adding lyase (1% lysozyme and 0.1% papain in percentage by weight) to perform lysis on probiotics for 4 hours, dissolving intracellular active substances, centrifuging at 8000rpm for 10 minutes, collecting supernatant, and filtering by a microporous filter membrane of 0.45 μm to remove insoluble substances to obtain the biological probiotic composition.
Comparative example 1:
a bio-prebiotic composition prepared by a bio-fermentation technique from the following raw materials: soybean, probiotics and prebiotics, the preparation method of the biological prebiotic composition comprises the following steps:
(1) Pulverizing semen glycines to 80 mesh, extracting with 90 deg.C hot water for 3 hr, cooling the extractive solution to 55deg.C, adding complex enzyme (0.1% alpha-amylase, 0.1% saccharifying enzyme, 0.1% papain) in weight percentage, performing enzymolysis for 2 hr, centrifuging at 8000rpm for 10min, collecting semen glycines extractive solution (protein content of 0.5% in weight percentage), sterilizing at 90deg.C, and cooling to 37deg.C;
(2) Preparing a bottom sugar solution: 1% of galacto-oligosaccharide and 1% of fructo-oligosaccharide are dissolved by purified water according to the weight percentage of the soybean fermentation liquid, and after sterilization at a high temperature of 90 ℃, the mixture is fed into the soybean extraction liquid prepared in the step (1) for one time before fermentation to obtain the soybean fermentation culture liquid;
(3) Preparing seed liquid: preparing seed liquid broth culture solution (1% by weight of casein enzyme digest, 1% by weight of beef extract powder, 1% by weight of yeast extract powder, and 2% by weight of glucose), sterilizing at high temperature, cooling to 37deg.C, inoculating strain tube containing Lactobacillus rhamnosus, bifidobacterium longum, and Bifidobacterium adolescentis, culturing in anaerobic shake flask at 37deg.C for 8 hr, and culturing to obtain bacterial liquid OD 600 About 1, wherein the probiotics are lactobacillus rhamnosus CGMCC NO.16103, bifidobacterium longum CGMCC NO.18094 and bifidobacterium adolescentis CICC 6175, and the probiotics are lactobacillus rhamnosus, bifidobacterium longum and bifidobacterium adolescentis in a weight ratio of 1:1:1;
(4) Inoculating the probiotic bacteria seed liquid prepared in the step (3) according to the proportion of 0.1% in the soybean fermentation culture liquid treated in the step (2) under the protection of flame, and fermenting for 24 hours at the low-temperature anaerobic temperature of 30 ℃;
(5) After fermentation, inactivating the bacterial activity at 75 ℃, cooling to 55 ℃, adding lyase (1% lysozyme and 0.1% papain in percentage by weight) to perform lysis on probiotics for 4 hours, dissolving intracellular active substances, centrifuging at 8000rpm for 10 minutes, collecting supernatant, and filtering by a microporous filter membrane of 0.45 μm to remove insoluble substances to obtain the biological probiotic composition.
Comparative example 2:
a biological probiotics composition with skin microecology regulating effect, which is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics, the preparation method of the biological prebiotic composition comprises the following steps:
(1) Pulverizing semen glycines to 80 mesh, extracting with 90 deg.C hot water for 3 hr, cooling the extractive solution to 55deg.C, adding complex enzyme (0.1% alpha-amylase, 0.1% saccharifying enzyme, 0.1% papain) in weight percentage, performing enzymolysis for 2 hr, centrifuging at 8000rpm for 10min, collecting semen glycines extractive solution (protein content of 0.5% in weight percentage), sterilizing at 90deg.C, and cooling to 37deg.C;
(2) Preparing a bottom sugar solution: 1% of galacto-oligosaccharide and 1% of fructo-oligosaccharide are dissolved by purified water according to the weight percentage of the soybean fermentation liquid, and after sterilization at a high temperature of 90 ℃, the mixture is fed into the soybean extraction liquid prepared in the step (1) for one time before fermentation to obtain the soybean fermentation culture liquid;
(3) Preparing seed liquid: preparing seed liquid broth culture solution (1% by weight of casein enzyme digest, 1% by weight of beef extract powder, 1% by weight of yeast extract powder, and 2% by weight of glucose), sterilizing at high temperature, cooling to 37deg.C, inoculating strain tube containing lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis, culturing in anaerobic shake flask at 37deg.C for 8 hr, and culturing to obtain bacterial liquid OD 600 About 1, the probiotics are lactobacillus rhamnosus ATCC53103, bifidobacterium longum ATCC15708, bifidobacterium adolescentis ATCC5703, streptococcus thermophilus ATCC19258, lactobacillus casei ATCC393 and bifidobacterium lactis TACC29521, and the probiotics are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis in a weight ratio of 1:1:1:1:1:1;
(4) Inoculating the probiotic bacteria seed liquid prepared in the step (3) according to the proportion of 0.1% in the soybean fermentation culture liquid treated in the step (2) under the protection of flame, and fermenting for 24 hours at the low-temperature anaerobic temperature of 30 ℃;
(5) After fermentation, inactivating the bacterial activity at 75 ℃, cooling to 55 ℃, adding lyase (1% lysozyme and 0.1% papain in percentage by weight) to perform lysis on probiotics for 4 hours, dissolving intracellular active substances, centrifuging at 8000rpm for 10 minutes, collecting supernatant, and filtering by a microporous filter membrane of 0.45 μm to remove insoluble substances to obtain the biological probiotic composition.
Comparative example 3:
a biological probiotics composition with skin microecology regulating effect, which is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics, the preparation method of the biological prebiotic composition comprises the following steps:
(1) Pulverizing semen glycines to 80 mesh, extracting with 90 deg.C hot water for 3 hr, cooling the extractive solution to 55deg.C, adding complex enzyme (0.1% alpha-amylase, 0.1% saccharifying enzyme, 0.1% papain) in weight percentage, performing enzymolysis for 2 hr, centrifuging at 8000rpm for 10min, collecting semen glycines extractive solution (protein content of 0.5% in weight percentage), sterilizing at 90deg.C, and cooling to 37deg.C;
(2) Preparing a bottom sugar solution: dissolving 2% galacto-oligosaccharide by using purified water according to the weight percentage of the soybean fermentation liquid, sterilizing at 90 ℃ and then supplementing the solution into the soybean extract prepared in the step (1) for one time before fermentation to obtain the soybean fermentation culture liquid;
(3) Preparing seed liquid: preparing seed liquid broth culture solution (1% by weight of casein enzyme digest, 1% by weight of beef extract powder, 1% by weight of yeast extract powder, and 2% by weight of glucose), sterilizing at high temperature, cooling to 37deg.C, inoculating strain tube containing lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis, culturing in anaerobic shake flask at 37deg.C for 8 hr, and culturing to obtain bacterial liquid OD 600 About 1, wherein the probiotics are lactobacillus rhamnosus CGMCC NO.16103, bifidobacterium longum CGMCC NO.18094, bifidobacterium adolescentis CICC 6175, streptococcus thermophilus CGMCC NO.18045, lactobacillus casei CGMCC NO.21373 and lactobacillus bifidus CGMCC NO.18093, and the probiotics are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis in a weight ratio of 1:1:1:1:1:1:1;
(4) Inoculating the probiotic bacteria seed liquid prepared in the step (3) according to the proportion of 0.1% in the soybean fermentation culture liquid treated in the step (2) under the protection of flame, and fermenting for 24 hours at the low-temperature anaerobic temperature of 30 ℃;
(5) After fermentation, inactivating the bacterial activity at 75 ℃, cooling to 55 ℃, adding lyase (1% lysozyme and 0.1% papain in percentage by weight) to perform lysis on probiotics for 4 hours, dissolving intracellular active substances, centrifuging at 8000rpm for 10 minutes, collecting supernatant, and filtering by a microporous filter membrane of 0.45 μm to remove insoluble substances to obtain the biological probiotic composition.
Comparative example 4:
a biological probiotics composition with skin microecology regulating effect, which is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics, the preparation method of the biological prebiotic composition comprises the following steps:
(1) Pulverizing semen glycines to 80 mesh, extracting with hot water at 90deg.C for 3 hr, cooling the extractive solution to 55deg.C, adding complex enzyme (0.2% alpha-amylase and 0.1% papain by weight percentage), performing enzymolysis for 2 hr, centrifuging at 8000rpm for 10min, collecting semen glycines extractive solution (protein content of 0.5% by weight percentage), sterilizing at 90deg.C, and cooling to 37deg.C;
(2) Preparing a bottom sugar solution: 1% of galacto-oligosaccharide and 1% of fructo-oligosaccharide are dissolved by purified water according to the weight percentage of the soybean fermentation liquid, and after sterilization at a high temperature of 90 ℃, the mixture is fed into the soybean extraction liquid prepared in the step (1) for one time before fermentation to obtain the soybean fermentation culture liquid;
(3) Preparing seed liquid: preparing seed liquid broth culture solution (1% by weight of casein enzyme digest, 1% by weight of beef extract powder, 1% by weight of yeast extract powder, and 2% by weight of glucose), sterilizing at high temperature, cooling to 37deg.C, inoculating strain tube containing lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis, culturing in anaerobic shake flask at 37deg.C for 8 hr, and culturing to obtain bacterial liquid OD 600 About 1, wherein the probiotics are lactobacillus rhamnosus CGMCC NO.16103, bifidobacterium longum CGMCC NO.18094, bifidobacterium adolescentis CICC 6175, streptococcus thermophilus CGMCC NO.18045, lactobacillus casei CGMCC NO.21373 and lactobacillus bifidus CGMCC NO.18093, and the probiotics are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis in a weight ratio of 1:1:1:1:1:1:1;
(4) Inoculating the probiotic bacteria seed liquid prepared in the step (3) according to the proportion of 0.1% in the soybean fermentation culture liquid treated in the step (2) under the protection of flame, and fermenting for 24 hours at the low-temperature anaerobic temperature of 30 ℃;
(5) After fermentation, inactivating the bacterial activity at 75 ℃, cooling to 55 ℃, adding lyase (1% lysozyme and 0.1% papain in percentage by weight) to perform lysis on probiotics for 4 hours, dissolving intracellular active substances, centrifuging at 8000rpm for 10 minutes, collecting supernatant, and filtering by a microporous filter membrane of 0.45 μm to remove insoluble substances to obtain the biological probiotic composition.
Effect examples:
effect example 1: effect of the inventive bioprotein composition on proliferation of staphylococcus epidermidis
Staphylococcus epidermidis can inhibit the activity of accessory gene regulator (SA agr) of Staphylococcus aureus, and reduce the colonisation of Staphylococcus aureus on skin surface. The staphylococcus epidermidis can produce a broad-spectrum bacteriocin, has bactericidal effect on other bacterial flora such as corynebacteria, streptococcus pneumoniae, neisseria and clostridium, and can inhibit the growth of harmful bacteria, and protect the skin and health of a host. Staphylococcus epidermidis can also relieve inflammation after infection, promote antibacterial peptide (AMP) expression and regulatory T cell activity, and inhibit conventional CD4 + T cell development. The staphylococcus epidermidis cell wall component reduces inflammation by binding TLR2, limits tissue damage and promotes wound healing. The experimental procedure of the staphylococcus epidermidis proliferation assay is shown in figure 1.
1. Preparation of bacterial suspension
A staphylococcus epidermidis (available from Haibo biotechnology Co., ltd., CMCC 26069) slant strain was collected, the slant lawn was washed with 3mL of PBS a few times in a 100mL reagent bottle, a proper amount of the washed bacterial liquid was taken into 9mL of PBS, and the concentration of the bacterial suspension was adjusted to 0.5 McO unit by using a Mitsubishi tube, which was approximately 1X 10 5 -9×10 5 cfu/g. (the concentration is required: 0.1mL was dropped into 5.0mL of a control sample solution (PBS), and the number of recovered bacteria was 1X 10) 4 -9×10 4 cfu/mL)
2. Operating procedure
(1) Diluting the test sample with sterile standard hard water to a specified concentration (1:10);
(2) Sucking 0.1mL of the test bacterial suspension, adding the test bacterial suspension into a test tube containing 5mL of diluted sample ((1)), quickly and uniformly mixing, and timing immediately;
(3) After 20min of action, 1mL of mixed solution of test bacteria and a sample is taken and added into a sterilized PBS test tube containing 9mL ((2)), and the mixture is fully and uniformly mixed; then, 1mL of the sample solution is sucked into a sterilized PBS test tube containing 9mL ((3)), and the sample solution is sufficiently and uniformly shaken;
(4) 1mL of the turbidimetric bacterial suspension was pipetted into a 9mL sterilized PBS tube (10) 7 ) Sequentially dilute to 10 6 、10 5 、10 4 、10 3 ；
(5) Sucking the sample solution dilutions (1), (2) and (3); turbidimetric diluent 10 3 、10 4 、10 5 1mL each was placed in a sterilization plate, and three sterilization plates were inoculated with each sample or dilution. Pouring 15mL of nutrient agar basic culture medium cooled to 40-45 ℃, rotating the plate to make the culture medium fully and uniformly, overturning the plate after agar solidification, culturing for 1-2 days at 37 ℃, and counting viable bacteria colonies;
(6) Experiments were repeated 3 times and their average value was calculated;
in addition: 1 (1:10) sample solution, 1 PBS solution, 1 standard hard aqueous solution were incubated as references.
3. Calculation formula
Proliferation (%) was calculated as follows.
Proliferation rate = (a-B)/a 100
Wherein:
a ┈ ┈ test sample average colony count;
average colony count of B ┈ ┈ control sample
4. Experimental results
The experimental results of the effect of the inventive bio-prebiotic composition on the proliferation of staphylococcus epidermidis are shown in table 1.
Table 1: effect of the inventive bioprotein composition on proliferation of staphylococcus epidermidis
| Group of | Proliferation Rate (%) |
| Example 1 | 45.39 |
| Comparative example 1 | 31.25 |
| Comparative example 2 | 34.57 |
| Comparative example 3 | 35.66 |
| Comparative example 4 | 37.21 |
The experimental results show that the example 1 group can significantly promote the proliferation of staphylococcus epidermidis compared with the comparative example group. Furthermore, from the experimental results of the comparative examples 1-2, it can be seen that the kind and the ratio of probiotics have a significant influence on the effect of the bio-prebiotic composition of the present invention on promoting staphylococcus epidermidis. In addition, as can be seen from the experimental results of comparative examples 3 to 4, the kind of prebiotics as a nutrient source of probiotics and the kind of complex enzyme for enzymatic hydrolysis of soybean aqueous extract and the ratio thereof have very significant influence on the effect of promoting staphylococcus epidermidis of the bio-prebiotic composition of the present invention.
Effect example 2: effect of the Bioprebiotic compositions of the invention on hyaluronidase Activity
Hyaluronic Acid (HA) in the intercellular matrix plays a major role in maintaining skin moisture and elasticity, wound healing and angiogenesis, allergic reactions, and the like. Inhibiting hyaluronidase activity can prevent decomposition of hyaluronic acid, maintain normal physiological function, and is helpful for relieving anaphylaxis, repairing skin injury, and delaying skin aging.
Hyaluronidase (HAase) can degrade hyaluronic acid, and studies show that Hyaluronidase has strong correlation with inflammation and allergy, and when there is internal heat symptoms such as inflammation in skin, hyaluronidase activity is increased. The anti-allergic experiment adopts an in vitro inhibition experiment of hyaluronidase to detect the effect of the test liquid on inhibiting the activity of the hyaluronidase so as to verify the anti-allergic and anti-irritation effects of the invention. Experimental tests were performed with a 10.0% concentration of the test substance. The results are shown in Table 2.
Table 2: effect of the Bioprebiotic compositions of the invention on hyaluronidase Activity
| Group of | Hyaluronidase inhibition rate (%) |
| Example 1 | 93.28 |
| Comparative example 1 | 69.43 |
| Comparative example 2 | 78.22 |
| Comparative example 3 | 82.45 |
| Comparative example 4 | 84.31 |
The experimental results show that the example 1 group has significantly stronger inhibition effect on hyaluronic acid than the comparative example group. Furthermore, as can be seen from the experimental results of the comparative examples 1-2, the kind and the ratio of probiotics have a significant influence on the effect of the bio-prebiotic composition of the present invention in inhibiting hyaluronidase. In addition, as can be seen from the experimental results of comparative examples 3 to 4, the kind of prebiotics as a nutrient source of probiotics and the kind of complex enzyme for enzymatic hydrolysis of soybean aqueous extract and the ratio thereof have very significant influence on the effect of inhibiting hyaluronidase of the bio-prebiotic composition of the present invention.
Effect example 3: the biological probiotics composition of the invention maintains the weak acid function of the skin
(1) 30 people from subjects between 16 and 65 years of age (except pregnant or lactating women). The subjects were required to have no serious systemic disease, no immunodeficiency or autoimmune disease, no active allergic disease, no serious allergic history of skin care cosmetics, no hormone drugs and no immunosuppressant in the last month, and no other clinical trials.
(2) Test group: skin lotion placebo and 2% bio-prebiotic group (using the bio-prebiotic composition prepared in example 1 of the present invention). It is applied by spraying on arm for 28 days for 1 time in the morning and evening.
(3) Before testing, the test kit should sit in a room (test environment temperature: 22+ -1deg.C, humidity: 50+ -5%, and real-time dynamic monitoring) meeting the standard for at least 30min, and cannot drink water, and the forearm is exposed, and is placed in a test state, and kept relaxed, and the measurement marks in the forearm of both hands are 3×3cm 2 The test area, a plurality of areas can be marked simultaneously by the same arm, and the intervals of the areas are 1cm.
(4) The pH of the subject before and after cleaning and sanitizing with sanitizing hand sanitizer was measured using a SKIN pH test probe SKIN-PH-METER PH 905.
The experimental results are shown in figure 2, and the experimental results show that the use of 2% of biological probiotics can reduce the pH rise of the skin caused by cleaning and sterilizing liquid and maintain the weak acidic pH value of the skin.Effect example 4: the biological probiotics composition pair group Amine stimulated soothing
1. Detection instrument:
skin sensitivity tester Tivi700.
2. The experimental method comprises the following steps:
(1) The inner arm of the volunteer (labeled area: 3 x 3 cm) was stimulated with 5% histamine hydrochloride solution, and the volunteer developed an allergic response of redness, swelling and itching, and was recorded.
(2) Dividing the sample group and the blank group in the identification area, and applying 20. Mu.L of the bio-prebiotic composition of the invention to the sample group (example 1); the blank was smeared with 20 μl of deionized water and recorded after 1 h.
3. Experimental results:
the experimental results are shown in Table 3, and in FIGS. 3A-3C and 4. Experimental results show that compared with a blank group, the biological probiotics can reduce skin anaphylactic reaction caused by histamine at the concentration of 2%, have obvious difference (P < 0.05) and have a relieving function.
Table 3: sensitivity Tivi value variation
| 2% group of biological probiotics | Blank control group | |
| Sample relieving (1 h) | -6.10％ | +2.94％ |
| Sample relieving (2 h) | -21.95％ | -10.29％ |
Effect example 5: the biological probiotics composition has the repairing effect on skin
(1) Cell inoculation: diluting 3T3 mouse fibroblast (purchased from cell bank of China academy of sciences, catalog number: GNM 25) with cell culture medium to inoculation density (fusion degree of 45% -60% 24h after inoculation), inoculating into 96-well plate with liquid amount of 200 μl per well, and placing into CO 2 Culturing in an incubator for 24+/-2 hours.
(2) Administration: the medium in the 96-well plate was discarded, and the administration was performed. The culture medium containing the test substance (the bio-prebiotic composition prepared using example 1 of the present invention) was added to the test substance wells, and normal cell culture medium was added to the blank/solvent control wells at 200 μl per well. After the end of dosing, 96-well plates were placed in CO 2 Culturing in an incubator for 24 hours plus or minus 2 hours.
(3) Cell supernatant collection: after the incubation, 200. Mu.L of the cell culture supernatant was collected in a 1.5mL sterile centrifuge tube and stored in an ultra-low temperature refrigerator at-80 ℃.
(4) ELISA detection: detection was performed according to the instructions for use of the mouse type i collagen enzyme-linked immunosorbent assay kit.
The experimental results are shown in table 4. Experimental results show that the biological probiotics prepared in the embodiment 1 of the invention can promote the synthesis of fibroblast type I collagen and has a repairing effect.
Table 4: effects of the Bioprebiotic compositions of the invention on collagen Synthesis by fibroblasts
Effect example 6: the biological probiotics composition has the inhibition effect on inflammatory factors in allergy
(1) Cell inoculation: dilution of macrophages with cell culture Medium (mouse aloneNuclear macrophage leukemia cell line RAW264.7, purchased from the national academy of sciences cell bank, catalog number: TCM 13) to inoculation density (24 h fusion degree reaches 45% -60% after inoculation), inoculating into 96-well plates with liquid amount of 200 μl per well, and placing into CO 2 Culturing in an incubator for 24+/-2 hours.
(2) Administration: the medium in the 96-well plate is discarded, and the induction and administration operations are performed. Test substance (using the Bioprobiotic composition prepared in example 1 of the present invention) the wells were filled with a medium containing a concentration of test substance and 1. Mu.g/mL LPS, the negative control wells were filled with a cell culture medium containing LPS, the blank control wells were filled with cell culture medium, 200. Mu.L of CO per well 2 Culturing in an incubator for 24+ -2 h.
(3) Cell supernatant collection: after the incubation, 200. Mu.L of the cell culture supernatant was collected in a 1.5mL sterile centrifuge tube and stored in an ultra-low temperature refrigerator at-80 ℃.
(4) ELISA detection: the assay was performed according to the instructions of the TNF- α ELISA assay kit.
The experimental results are shown in table 5. Experimental results show that compared with a model group, 0.1% of the biological probiotics can obviously reduce the secretion of macrophage inflammatory factor (TNF-alpha) under the stimulation of LPS.
Table 5: inhibition of TNF-alpha cytokines by the biological prebiotic compositions of the invention
In summary, the bio-prebiotic composition of the present invention and the cosmetic containing the same have the composite effects of regulating skin micro-ecology, maintaining weak acid function of skin, relieving skin anaphylaxis, inhibiting inflammatory factors in anaphylaxis and promoting skin repair.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (10)
1. A biological probiotic composition having a skin micro-ecological regulating effect, characterized in that: the bioprotein composition comprises soy isoflavones, soy amino acids, probiotic lysates, and probiotic fermentation products.
2. The bio-prebiotic composition of claim 1 wherein: the biological probiotics composition is prepared from the following raw materials by a biological fermentation technology: soybean, probiotics and prebiotics.
3. The bio-prebiotic composition of claim 2 wherein: the probiotics are selected from one or more of the following: lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei or bifidobacterium lactis; the prebiotic is selected from one or more of the following: lactose, sucrose, fructo-oligosaccharides, galacto-oligosaccharides or malto-oligosaccharides.
4. A bio-prebiotic composition according to claim 3, wherein: lactobacillus rhamnosus, bifidobacterium longum and bifidobacterium adolescentis are isolated from the intestinal tracts of healthy adult people in the Guangxi Bama longevity village; streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis are isolated from self-made fermented yoghurt by herdsmen in Yili, xinjiang.
5. The bioprotectant composition of claim 3 or claim 4, wherein: the probiotics are lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium adolescentis, streptococcus thermophilus, lactobacillus casei and bifidobacterium lactis; the prebiotics are fructo-oligosaccharides and galacto-oligosaccharides.
6. A process for the preparation of a bio-prebiotic composition according to any of claims 1 to 5, characterized in that: the preparation method comprises the following steps:
(1) Pulverizing semen glycines, extracting with hot water, adding complex enzyme into the extractive solution, centrifuging, collecting semen glycines extractive solution, sterilizing at high temperature, and cooling to 37deg.C;
(2) Adding probiotics and prebiotics into the soybean extract prepared in the step (1), and fermenting at low temperature for 24 hours;
(3) After fermentation, adding lyase to perform lysis on the probiotics, dissolving out intracellular active substances, and filtering by a microporous filter membrane to remove insoluble substances to obtain the biological probiotics composition.
7. The method of manufacturing according to claim 6, wherein: the complex enzyme in step (1) is selected from one or more of the following: amylase, saccharifying enzyme or protease, the low temperature in step (2) is 30 ℃.
8. Use of a bio-prebiotic composition according to any one of claims 1 to 5 or prepared by a preparation method according to claim 6 or claim 7 for the preparation of a cosmetic for regulating the microecological balance of skin.
9. Use according to claim 8, characterized in that: the cosmetic has effects of regulating skin microecology, maintaining weak acid function of skin, relieving skin anaphylaxis, inhibiting inflammatory factor in anaphylaxis, and promoting skin repair, and can be used for daily skin care, sensitive muscle care, acne skin care, deodorant care, infant skin care or scalp care.
10. Use according to claim 8 or claim 9, characterized in that: the cosmetic is toner, emulsion, essence, cream or facial mask, and the dosage of the biological probiotics composition in the cosmetic is 1-10% by weight percent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310892869.0A CN116919879A (en) | 2023-07-20 | 2023-07-20 | Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310892869.0A CN116919879A (en) | 2023-07-20 | 2023-07-20 | Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116919879A true CN116919879A (en) | 2023-10-24 |
Family
ID=88378571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310892869.0A Pending CN116919879A (en) | 2023-07-20 | 2023-07-20 | Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116919879A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006048457A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Probiotica and polyphenol |
| KR102153414B1 (en) * | 2020-05-18 | 2020-09-09 | 서울대학교산학협력단 | Composition for improving hair loss and promoting hair growth containing a fermented soybean |
| CN111991280A (en) * | 2020-07-15 | 2020-11-27 | 杨庆瑞 | Anti-allergy bean fermentation extract, product and preparation method thereof |
| CN112980892A (en) * | 2021-03-02 | 2021-06-18 | 山东艾益典生物技术有限公司 | Composite probiotic fermented product with skin care effect and preparation and application thereof |
| CN116077415A (en) * | 2023-02-28 | 2023-05-09 | 广州市望莎精细化工有限公司 | Ternary probiotic factor composition for regulating skin microecological balance |
-
2023
- 2023-07-20 CN CN202310892869.0A patent/CN116919879A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006048457A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Probiotica and polyphenol |
| KR102153414B1 (en) * | 2020-05-18 | 2020-09-09 | 서울대학교산학협력단 | Composition for improving hair loss and promoting hair growth containing a fermented soybean |
| CN111991280A (en) * | 2020-07-15 | 2020-11-27 | 杨庆瑞 | Anti-allergy bean fermentation extract, product and preparation method thereof |
| CN112980892A (en) * | 2021-03-02 | 2021-06-18 | 山东艾益典生物技术有限公司 | Composite probiotic fermented product with skin care effect and preparation and application thereof |
| CN116077415A (en) * | 2023-02-28 | 2023-05-09 | 广州市望莎精细化工有限公司 | Ternary probiotic factor composition for regulating skin microecological balance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102533618B (en) | Lactobacillus plantarum CCFM8724 and application thereof | |
| CN102071162B (en) | Bacillus subtilis LFB112 as well as bacteriocin produced by same and application thereof | |
| CN113088463B (en) | Lactobacillus acidophilus with probiotic characteristics and application thereof | |
| CN101328469B (en) | Streptococcus thermophilus grx02 having alcoholic liver damage protection function and use thereof | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN105586299A (en) | Lactobacillus acidophilus preparation and application thereof | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| Goa et al. | Isolation and characterization of lactic acid bacteria from fermented milk produced in Jimma Town, Southwest Ethiopia, and evaluation of their antimicrobial activity against selected pathogenic bacteria | |
| CN109498660A (en) | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN116077415B (en) | Ternary probiotic factor composition for regulating skin microecological balance | |
| CN110835615B (en) | Active substance of bifidobacterium lactis GKK2, composition containing same and application of active substance and composition in promoting longevity | |
| CN110835614B (en) | Bifidobacterium lactis GKK2, composition containing same and application of composition in improving allergic asthma | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN111567807A (en) | Rhamnose-containing lactobacillus composition for inhibiting inflammatory reaction and resisting vaginitis and application thereof | |
| CN114657106B (en) | Lactobacillus plantarum and application thereof in preventing and treating acne | |
| Ray | Probiotics of lactic acid bacteria: science or myth? | |
| Irza et al. | Isolation, Characterization, Molecular Identification of Probiotic Bacteria from Meconium | |
| CN116919879A (en) | Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof | |
| RU2273662C2 (en) | Consortium of microorganisms with probiotic effect | |
| CN103555604A (en) | Lactobacillus salivarius capable of inhibiting Candida albicans growth, and separation method thereof | |
| Shirisha et al. | Isolation and characterization of probiotics from different curd samples | |
| Doğan et al. | Assessment of probiotic properties of lactic acid bacteria from traditional sourdoughs for bread-making in turkey against some gut conditions | |
| TWI600758B (en) | Immunnomodulatory Lactobacillus plantarum and use thereof | |
| CN115624573B (en) | Probiotic composition for improving hair health condition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240411 Address after: 8-8, 8th Floor, Global Center, No. 295 Qiaoyuan North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province, 315000 (Juhe) Applicant after: Ningbo Hecaoji Brand Management Co.,Ltd. Country or region after: China Address before: 511547 No. 11, guangtuo street, Guangqing Industrial Park, Shijiao Town, Qingcheng District, Qingyuan City, Guangdong Province Applicant before: Qingyuan Wangsha Biotechnology Co.,Ltd. Country or region before: China |